NASDAQ:ANAB AnaptysBio Q2 2026 Earnings Results & Report $46.04 +0.09 (+0.20%) Closing price 10/12/2026 04:00 PM EasternExtended Trading$46.08 +0.05 (+0.10%) As of 10/12/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. AnaptysBio beat analyst expectations on both earnings and revenue in its Q2 2026 results, released September 21, 2026. The company reported EPS of $5.11 versus the -$0.4650 consensus estimate, while revenue of $27.49 million topped the $14.06 million estimate by $13.43 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateSeptember 21, 2026TimeAfter Market ClosesConference Call4:00 PM ET AnaptysBio EPS ResultsActual EPS$5.11Consensus EPS -$0.4650Beat/MissBeat by +$5.5750One Year Ago EPS-$1.30EPS Beat Rate7 of last 8 quartersAnaptysBio Revenue ResultsActual Revenue$27.49 millionExpected Revenue$14.06 millionBeat/MissBeat by +$13.43 millionYoY Revenue GrowthN/AUpcoming EarningsAnaptysBio's Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) AnaptysBio Q2 2026 Earnings FAQ Did AnaptysBio beat earnings estimates for Q2 2026? AnaptysBio (NASDAQ:ANAB) reported earnings of $5.11 per share for Q2 2026, beating the consensus estimate of -$0.4650. The report was announced on Monday, September 21, 2026. What was AnaptysBio's revenue for Q2 2026? AnaptysBio reported revenue of $27.49 million for Q2 2026, against a consensus estimate of $14.06 million. When is AnaptysBio's next earnings date? AnaptysBio's next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for AnaptysBio on the company's earnings history page. AnaptysBio Earnings HeadlinesWhy this IPO stock, an AnaptysBio spinoff, just skyrocketed more than 25%October 12 at 1:32 PM | msn.comAnaptysBio (ANAB) Stock Looks Undervalued Even After A 273% RiseOctober 9, 2026 | finance.yahoo.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely. | Altimetry (Ad)AnaptysBio (ANAB) Could Be 49% Undervalued On Its Royalty StoryOctober 9, 2026 | finance.yahoo.comAnaptysBio (NASDAQ:ANAB) Cut to Hold at Wall Street ZenOctober 4, 2026 | americanbankingnews.comAnaptysBio (NASDAQ:ANAB) Director Hollings Renton Sells 5,000 Shares of Company StockOctober 3, 2026 | americanbankingnews.comSee More AnaptysBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AnaptysBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AnaptysBio and other key companies, straight to your email. Email Address About AnaptysBioAnaptysBio (NASDAQ:ANAB) is a clinical-stage biotechnology company focused on developing antibody-based medicines for inflammatory and autoimmune diseases. The company uses its antibody discovery and engineering capabilities to identify therapies designed to modulate immune-system targets involved in disease. AnaptysBio’s pipeline has included rosnilimab, an investigational antibody designed to target CD200R1, a receptor involved in regulating immune-cell activity. The company has evaluated rosnilimab in inflammatory and autoimmune conditions, including rheumatoid arthritis and ulcerative colitis. Its development programs and priorities may change as clinical studies progress. Founded in 2005 and headquartered in San Diego, California, AnaptysBio has also pursued collaborations and licensing arrangements with larger pharmaceutical companies. Historically, antibodies discovered using the company’s technology have contributed to programs such as dostarlimab, an immune checkpoint inhibitor subsequently developed and commercialized by another company. AnaptysBio is led by President and Chief Executive Officer Hamid Tabatabai.View AnaptysBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
